CBX3 and posterior cortical atrophy: Notably, a recent study revealed that CK2 inhibitors disrupt CK2-mediated phosphorylation of CBX3, thereby inhibiting the subsequent ubiquitination and degradation of CBX3 and ultimately enhancing the efficacy of PARP inhibitors in PCa treatment (34).